SEC Form 4 · accession 0001209191-16-129917
ReShape Lifesciences Inc. · RSLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott A Shikora
Officer — EVP & Chief Medical Officer
Period of report
Jun 27, 2016
Accepted (ET)
Jun 28, 2016 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001371217
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3,F2 | $16.80 | Jun 27, 2016 | D | 25,000 | D | Jun 1, 2016 | Apr 21, 2025 | Common Stock | 25,000 | 0 | D |
| Stock Option (Right to Buy)F5,F4 | $0.3325 | Jun 27, 2016 | A | 5,507 | A | Jun 27, 2016 | Jun 27, 2023 | Common Stock | 5,507 | 5,507 | D |
| Stock Option (Right to Buy)F1,F3,F6 | $16.80 | Jun 27, 2016 | D | 25,000 | D | Jul 1, 2016 | Apr 21, 2025 | Common Stock | 25,000 | 0 | D |
| Stock Option (Right to Buy)F5,F4 | $0.3325 | Jun 27, 2016 | A | 5,507 | A | Jun 27, 2016 | Jun 27, 2023 | Common Stock | 5,507 | 5,507 | D |
Explanation of responses
- F1On January 6, 2016, EnteroMedics Inc. effected a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
- F2Vests as to 25% on date noted and thereafter in cumulative installments of 1/36th per month.
- F3On June 27, 2016, this option was tendered by the reporting person pursuant to EnteroMedics' option exchange offer and was cancelled by the company at the expiration of the offer (see footnote 5).
- F4Options vest 33% on date noted and thereafter at 1/24th per month.
- F5On June 27, 2016, in exchange for the cancelled option referenced in footnote 3, the company granted the reporting person a replacement option for the number of shares reflected in column 9 of this line item at the exercise price noted in column 2 of this line item
- F6Vests in increments of 1/36th per month, beginning the date shown.